Kogure K, Okuda O, Itoh T, Hayashi K, Ueno M
Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, Sugitani, Japan.
Biol Pharm Bull. 1997 May;20(5):581-3. doi: 10.1248/bpb.20.581.
In order to develop a membrane fusible drug carrier from human erythrocytes, we attempted the reconstitution of influenza virus fusion protein hemagglutinin (HA) to an erythrocyte membrane. In this study, we succeeded in the preparation of HA-reconstituted erythrocytes (HA-erythrocytes) by the incubation of erythrocytes with influenza virus-infected CV-1 cells, and confirmed the ability of HA-erythrocytes to fuse with the cell membrane. Furthermore, by using an HA-reconstituted ghost (HA-ghost), which entrapped fluorescent-labeled ovalbumin, 25% of the protein was incorporated into cells through the fusion of the HA-ghost with the cell membrane.
为了从人红细胞开发一种膜融合性药物载体，我们尝试将流感病毒融合蛋白血凝素（HA）重构到红细胞膜上。在本研究中，我们通过将红细胞与流感病毒感染的CV-1细胞孵育，成功制备了HA重构红细胞（HA-红细胞），并证实了HA-红细胞与细胞膜融合的能力。此外，通过使用包裹有荧光标记卵清蛋白的HA重构血影（HA-血影），25%的蛋白质通过HA-血影与细胞膜的融合而进入细胞。
